Clincosm LogoSign in Get a demo

anlotinib

Showing 1 - 24 of 24
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, TKI Resistance, EGFR Sensitive Mutation Trial (Anlotinib, Penpulimab)

Not yet recruiting
  • Lung Cancer
  • +4 more
  • (no location specified)
Sep 15, 2023

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Anlotinib Hydrochloride
  • TACE
  • Lanzhou, Gansu, China
  • +3 more
Jan 12, 2023

Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib Trial in Shanghai (drug, radiation, procedure)

Recruiting
  • Soft Tissue Sarcoma
  • +3 more
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Nov 1, 2022

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

Neoadjuvent, PD-1 Inhibitor, Lung Cancer Trial in Xi'an (neoadjuvant PD-1 inhibitor, anlotinib combined with chemo)

Recruiting
  • Neoadjuvent
  • +4 more
  • neoadjuvant PD-1 inhibitor, anlotinib combined with chemotherapy
  • Xi'an, China
    Tangdu Hospital, the Air Force Military University
May 26, 2022

Ovarian Carcinoma, Survival Outcomes, Adverse Events Trial in Beijing (Niraparib plus anlotinib)

Recruiting
  • Ovarian Carcinoma
  • +8 more
  • Niraparib plus anlotinib
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Sarcoma,Soft Tissue, Extremity, Trunk Trial in Beijing (Anlotinib HCl)

Recruiting
  • Sarcoma,Soft Tissue
  • +5 more
  • Anlotinib hydrochloride
  • Beijing, Beijing, China
    Radiotherapy Department of Cancer Hospital, Chinese Academy of M
Dec 20, 2021

Neoadjuvant Treatment, Rectal Cancer, Anlotinib Trial (Anlotinib+Capeox, Capeox)

Withdrawn
  • Neoadjuvant Treatment
  • +2 more
  • (no location specified)
Sep 22, 2021

Urothelial Carcinoma, Anlotinib, Urogenital Tumors Trial in Tianjin (Anlotinib, Cisplatin, Carboplatin)

Not yet recruiting
  • Urothelial Carcinoma
  • +6 more
  • Tianjin, China
    Tianjin Medical Unversity Second Hospital
Aug 30, 2021

Ovarian Tumors, Fallopian Tube Tumors, Tumors by Site Trial (Drug: Anlotinib, Drug: Carboplatin/Paclitaxel)

Not yet recruiting
  • Ovarian Neoplasms
  • +14 more
  • Drug: Anlotinib
  • Drug: Carboplatin/Paclitaxel
  • (no location specified)
Mar 17, 2021

Anlotinib, Anti-PD-1 Antibody, Advanced Pancreatic Cancer Trial in Beijing (Anlotinib plus AK105)

Not yet recruiting
  • Anlotinib
  • +2 more
  • Anlotinib plus AK105
  • Beijing, Beijing, China
    Department of Medical Oncology, Peking Union Medical College Hos
Mar 16, 2021

SHR-1210, Anlotinib, Advanced Esophageal Squamous Cell Cancer Trial (SHR-1210 plus Anlotinib)

Not yet recruiting
  • SHR-1210
  • +2 more
  • SHR-1210 plus Anlotinib
  • (no location specified)
Mar 11, 2021

Hepatocellular Carcinoma, Thermal Ablation, Anlotinib Trial in Beijing (Anlotinib and TQB2450 solution, TQB2450 solution)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • Anlotinib and TQB2450 solution
  • TQB2450 solution
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Mar 2, 2021

Relapsed Small Cell Lung Cancer, Anlotinib Trial in Hangzhou (anlotinib HCl combined with irinotecan or docetaxel)

Recruiting
  • Relapsed Small Cell Lung Cancer
  • Anlotinib
  • anlotinib hydrochloride combined with irinotecan or docetaxel
  • Hangzhou, Zhejiang, China
    Affiliated Hangzhou Cancer Hospital, Zhejiang University School
Feb 14, 2021

Gastric Cancer, Gastro-oesophageal Junction Cancer, Immunotherapy Trial in Shanghai (Anlotinib Plus Toripalimab)

Recruiting
  • Gastric Cancer
  • +4 more
  • Anlotinib Plus Toripalimab
  • Shanghai, China
    Department of Medical Oncology, Shanghai Changzheng Hospital
Dec 28, 2020

Colorectal Cancer, Immunotherapy, Anlotinib Trial in Shanghai (Anlotinib plus Sintilimab)

Recruiting
  • Colorectal Cancer
  • +5 more
  • Anlotinib plus Sintilimab
  • Shanghai, China
    Department of Medical Oncology, Shanghai Changzheng Hospital
Dec 28, 2020

SCLC, Anlotinib Trial in Shanghai (Anlotinib HCl, Etoposide, Carboplatin)

Unknown status
  • SCLC
  • Anlotinib
  • Anlotinib hydrochloride
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Chest hospital
Dec 22, 2020

Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Tumors, Tumors by Site Trial in Nanjing (Anlotinib, Olaparib)

Recruiting
  • Ovarian Cancer
  • +18 more
  • Nanjing, Jangsu, China
    JiangSu Cancer Hospital
Oct 29, 2020

Breast Tumor, Antineoplastic Agents, Anlotinib Trial in Beijing (Anlotinib Hydrochloride)

Completed
  • Breast Neoplasm
  • +2 more
  • Anlotinib Hydrochloride
  • Beijing, Beijing, China
    National Cacner Center/ Cancer Hospital,Chinese Academy of Medic
Jul 27, 2020

Anlotinib, Durvalumab, Small Cell Lung Cancer Trial (Anlotinib In Combination With Durvalumab)

Unknown status
  • Anlotinib
  • +2 more
  • Anlotinib In Combination With Durvalumab
  • (no location specified)
Mar 17, 2020

NSCLC, Anlotinib, PD-1/L1 Inhibitor Trial (Anlotinib In Combination With PD-1/L1 Inhibitor)

Unknown status
  • NSCLC
  • +2 more
  • Anlotinib In Combination With PD-1/L1 Inhibitor
  • (no location specified)
Mar 16, 2020

Combination of Anlotinib and JS001 in EGFR-TKI Resistant

Unknown status
  • NSCLC Stage IV
  • +3 more
    • Shanghai, China
      Shanghai Changzheng Hospital
    Oct 3, 2019

    Lung Tumors, Docetaxel, Pemetrexed Trial in Lianyungang (anlotinib plus chemo, chemo)

    Unknown status
    • Lung Neoplasms
    • +4 more
    • Lianyungang, Jiangsu, China
      The Affiliated Lianyungang Hospital of Xuzhou Medical University
    Jul 16, 2018